Genetic Testing Company | The DNA Diagnostic Experts | GeneDx

In observance of Thanksgiving, GeneDx will be closed and will not accept specimens on Thursday, November 26, 2015. We will accept specimens but operate on a modified schedule on Friday, November 27, 2015.  We will resume our normal schedule on Saturday, November 28, 2015.  If you have any questions or inquiries, please call us at 301-519-2100 or email us at

TP53 Gene Sequencing



Clinical Utility:
  • Confirmation of a clinical diagnosis
  • Differentiation between hereditary breast and ovarian cancer syndrome (BRCA1, BRCA2 genes)
  • Identification of family members at-risk to develop cancers related to LFS
  • To determine an appropriate surveillance and treatment protocol
  • Prenatal diagnosis in families with a known mutation
Lab Method:
Capillary Sequencing


Test Code:
Turnaround Time:
4-5 weeks
Preferred Specimen:
2-5 mL Blood - Lavender Top Tube
Alternative Specimen:
Oral Rinse (30-40 mL)


CPT Codes:
New York Approved:
ABN Required:
Billing Information:
View Billing Policy
* For ICD9 to ICD10 conversion please follow this link
ICD-9 Codes:
  • 194: Malignant neoplasm of other endocrine glands and related structures Excludes: islets of Langerhans (157.4) neuroendocrine tumors (209.00-209.69) ovary (183.0) testis (186.0-186.9) thymus (164.0)
  • 174: Malignant neoplasm of female breast Includes: breast (female) connective tissue soft parts
  • 191: Malignant neoplasm of brain Excludes: cranial nerves (192.0) retrobulbar area (190.1)
  • 171: Malignant neoplasm of connective and other soft tissue Includes: blood vessel bursa fascia fat ligament, except uterine muscle peripheral, sympathetic, and parasympathetic nerves and ganglia synovia tendon (sheath) Excludes: cartilage (of): articular (170.0-170.9) larynx (161.3) nose (160.0) connective tissue: breast (174.0-175.9) internal organs code to malignant neoplasm of the site [e.g., leiomyosarcoma of stomach, 151.9] heart (164.1) uterine ligament (183.4)
* For price inquiries please email


  1. Birch et al., (1994) Cancer Res 54 :1298-1304.
  2. Bougeard et al., (2003) Oncogene 22:840-846.
  3. Eeles et al., (1995) Cancer Surv 25 :101-124.
  4. Ginsburg et al., (2009) Fam Cancer 8:563-567.
  5. Gonzalez et al., (2009) J Clin Oncol 27:1250-1256.
  6. Gonzalez et al., (2009) J Med Genet 46 :689-693.
  7. Li et al., (1988) Cancer Res 48:5358-5362.
  8. Tinat et al., (2009) J Clin Oncol 27(26):e108-e109.
  9. Varley et al., (2003) Hum Mutat 21:313-320.

Back To Top